| Product Unit Size | Cost | Quantity | Stock |
|---|
TAK 632 is a benzothiazole pan-Raf inhibitor that displays anticancer chemotherapeutic activity. TAK 632 induces dimerization of Raf but prevents kinase activity. This compound inhibits cellular proliferation of melanoma cells and inhibits tumor growth in animal models of melanoma.
| Cas No. | 1228591-30-7 |
|---|---|
| Purity | ≥99% |
| Formula | C27H18F4N4O3S |
| Formula Wt. | 554.52 |
| IUPAC Name | N-{7-Cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide |
| Synonym | TAK632 |
| Solubility | DMSO 100 mg/mL (180.33 mM) Ethanol 2 mg/mL (3.6 mM) Water Insoluble |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Nakamura A, Arita T, Tsuchiya S, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Dec 1;73(23):7043-55. PMID: 24121489.
Okaniwa M, Hirose M, Arita T, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. PMID: 23906342.